# Earnings review â€“ Madrigal (MDGL)

This note is for educational purposes only and is not investment advice.

## Stub
- Conceptual rating / target:
- Quarter reviewed:
- Reported date:

## Key takeaways
- Revenue vs consensus:
- Rezdiffra launch metrics vs expectations:
- Guidance changes:
- Management commentary highlight:

## P&L snapshot
- Total revenue:
- Product revenue detail:
- Operating expenses (R&D, SG&A):
- Cash and runway commentary:

## Launch and commercial update
- Patient starts / adherence / discontinuations:
- Payer coverage progress:
- Prescriber base evolution:

## Model implications
- rNPV assumptions adjusted:
- Scenario mix (bear/base/bull) impact:
- Other thesis-level considerations:
